Your browser doesn't support javascript.
loading
Challenges facing drug utilization research in the Latin American region.
Salas, Maribel; Lopes, Luciane C; Godman, Brian; Truter, Ilse; Hartzema, Abraham G; Wettermark, Bjorn; Fadare, Joseph; Burger, Johanita R; Appenteng, Kwame; Donneyong, Macarius; Arias, Ariel; Ankrah, Daniel; Ogunleye, Olayinka O; Lubbe, Martha; Horne, Laura; Bernet, Jorgelina; Gómez-Galicia, Diana L; Del Carmen Garcia Estrada, Miriam; Oluka, Margaret N; Massele, Amos; Alesso, Luis; Herrera Comoglio, Raquel; da Costa Lima, Elisangela; Vilaseca, Carmen; Bergman, Ulf.
Afiliación
  • Salas M; Daiichi Sankyo, Inc, Basking Ridge, USA.
  • Lopes LC; CCEB/CPeRT, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
  • Godman B; Pharmaceutical Science graduate Course, Universidade de Sorocaba UNISO, Sao Paulo, Brazil.
  • Truter I; Karolinska Institute, Stockholm, Sweden.
  • Hartzema AG; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Gainesville, Glasgow, UK.
  • Wettermark B; School of Pharmacy, Sefako Makgatho Health Sciences University, Garankuwa, South Africa.
  • Fadare J; Drug Utilization Research Unit (DURU), Department of Pharmacy, Nelson Mandela University, South Africa.
  • Burger JR; College of Pharmacy, Gainesville, FL.
  • Appenteng K; Clinical epidemiology & Clinical pharmacology, Karolinska Institutet, Stockholm, Sweden.
  • Donneyong M; Department of Pharmacy, Disciplinary Domain of Medicine and Pharmacy, Uppsala University.
  • Arias A; Department of Pharmacology and Therapeutics, Ekiti State University College of Medicine, Ado-Ekiti, Nigeria.
  • Ankrah D; Medicine Usage in South Africa (MUSA), North-West University, Potchefstroom, South Africa.
  • Ogunleye OO; Department of Epidemiology, Astellas Pharma US, Northbrook, IL.
  • Lubbe M; Pharmacy Practice and Science, College of Pharmacy, The Ohio State University, Columbus, Ohio.
  • Horne L; Centre for Biologics Evaluation, Health Canada, Ottawa, ON and Faculty of Pharmacy, Université de Montréal, Montreal, QC, Canada.
  • Bernet J; Korle-Bu Teaching Hospital, Accra, Ghana.
  • Gómez-Galicia DL; Department of Pharmacology, Therapeutics and Toxicology, Lagos State University College of Medicine, Ikeja, Lagos, Nigeria.
  • Del Carmen Garcia Estrada M; Medicine Usage in South Africa (MUSA), North-West University, Potchefstroom, South Africa.
  • Oluka MN; Department of Epidemiology, Daiichi Sankyo, Inc, Basking Ridge, NJ.
  • Massele A; School of Medicine, Cordoba National University, Cordoba, Argentina.
  • Alesso L; Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca, México.
  • Herrera Comoglio R; Facultad de Ciencias Medicas, Universidad de San Carlos de Guatemala, Guatemala, Guatemala.
  • da Costa Lima E; School of Pharmacy, University of Nairobi, Nairobi, Kenya.
  • Vilaseca C; Faculty of Medicine, University of Botswana, Gaborone, Botswana.
  • Bergman U; School of Medicine, Cordoba National University, Cordoba, Argentina.
Pharmacoepidemiol Drug Saf ; 29(11): 1353-1363, 2020 11.
Article en En | MEDLINE | ID: mdl-32419226
ABSTRACT

PURPOSE:

The International Society of Pharmacoepidemiology (ISPE) in collaboration with the Latin America Drug Utilization Research Group (LatAm DURG), the Medicines Utilization Research in Africa (MURIA) group, and the Uppsala Monitoring Center, is leading an initiative to understand challenges to drug utilization research (DUR) in the Latin American (LatAm) and African regions with the goal of communicating results and proposing solutions to these challenges in four scientific publications. The purpose of this first manuscript is to identify the main challenges associated with DUR in the LatAm region.

METHODS:

Drug utilization (DU) researchers in the LatAm region voluntarily participated in multiple discussions, contributed with local data and reviewed successive drafts and the final manuscript. Additionally, we carried out a literature review to identify the most relevant publications related to DU studies from the LatAm region.

RESULTS:

Multiple challenges were identified in the LatAm region for DUR including socioeconomic inequality, access to medical care, complexity of the healthcare system, limited investment in research and development, limited institutional and organization resources, language barriers, limited health education and literacy. Further, there is limited use of local DUR data by decision makers particularly in the identification of emerging health needs coming from social and demographic transitions.

CONCLUSIONS:

The LatAm region faces challenges to DUR which are inherent in the healthcare and political systems, and potential solutions should target changes to the system.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Utilización de Medicamentos / Motivación Límite: Humans Idioma: En Revista: Pharmacoepidemiol Drug Saf Asunto de la revista: EPIDEMIOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Utilización de Medicamentos / Motivación Límite: Humans Idioma: En Revista: Pharmacoepidemiol Drug Saf Asunto de la revista: EPIDEMIOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos